Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars

  • Posted by: Biocon Biologics

Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs

  • Posted by: Biocon Biologics

U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers

  • Posted by: Biocon Biologics

European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim

  • Posted by: Biocon Biologics

Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India

  • Posted by: Biocon Biologics

Resubmission of Biosimilar Trastuzumab and Pegfilgrastim Dossiers with EMA

  • Posted by: Biocon Biologics

Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore

  • Posted by: Biocon Biologics

Biocon Ranked Among Top 10 Global Pharma & Biotech Employers

  • Posted by: Biocon Biologics

US FDA Issues Complete Response Letter for Proposed Biosimilar Pegfilgrastim

  • Posted by: Biocon Biologics

Biocon’s Insulins facility in Malaysia Receives EU GMP Compliance Certificate

  • Posted by: Biocon Biologics
Share
buy twitter followers